Literature DB >> 26276903

State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.

Malika Faouzi1,2, John Starkus1,2, Reinhold Penner1,2.   

Abstract

BACKGROUND AND
PURPOSE: Kv 1.3 potassium channels are promising pharmaceutical targets for treating immune diseases as they modulate Ca(2+) signalling in T cells by regulating the membrane potential and with it the driving force for Ca(2+) influx. The antimycobacterial drug clofazimine has been demonstrated to attenuate antigen-induced Ca(2+) oscillations, suppress cytokine release and prevent skin graft rejection by inhibiting Kv 1.3 channels with high potency and selectivity. EXPERIMENTAL APPROACH: We used patch-clamp methodology to investigate clofazimine's mechanism of action in Kv 1.3 channels expressed in HEK293 cells. KEY
RESULTS: Clofazimine blocked Kv 1.3 channels by involving two discrete mechanisms, both of which contribute to effective suppression of channels: (i) a use-dependent open-channel block during long depolarizations, resulting in accelerated K(+) current inactivation and (ii) a block of closed deactivated channels after channels were opened by brief depolarizations. Both modes of block were use-dependent and state-dependent in that they clearly required prior channel opening. The clofazimine-sensitive closed-deactivated state of the channel was distinct from the resting closed state because channels at hyperpolarized voltages were not inhibited by clofazimine. Neither were channels in the C-type inactivated state significantly affected. Kv 1.3 channels carrying the H399T mutation and lacking C-type inactivation were insensitive to clofazimine block of the closed-deactivated state, but retained their susceptibility to open-channel block. CONCLUSIONS AND IMPLICATIONS: Given the prominent role of Kv 1.3 in shaping Ca(2+) oscillations, the use-dependent and state-dependent block of Kv 1.3 channels by clofazimine offers therapeutic potential for selective immunosuppression in the context of autoimmune diseases in which Kv 1.3-expressing T cells play a significant role.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26276903      PMCID: PMC4687807          DOI: 10.1111/bph.13283

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation.

Authors:  D C Hanson; A Nguyen; R J Mather; H Rauer; K Koch; L E Burgess; J P Rizzi; C B Donovan; M J Bruns; P C Canniff; A C Cunningham; K A Verdries; E Mena; J C Kath; G A Gutman; M D Cahalan; S Grissmer; K G Chandy
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 2.  Molecular properties and physiological roles of ion channels in the immune system.

Authors:  M D Cahalan; H Wulff; K G Chandy
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

3.  Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.

Authors:  L Leanza; L Trentin; K A Becker; F Frezzato; M Zoratti; G Semenzato; E Gulbins; I Szabo
Journal:  Leukemia       Date:  2013-02-21       Impact factor: 11.528

4.  Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.

Authors:  Tobias Dreker; Stephan Grissmer
Journal:  Mol Pharmacol       Date:  2005-07-06       Impact factor: 4.436

5.  Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Authors:  Alexander Schmitz; Ananthakrishnan Sankaranarayanan; Philippe Azam; Kristina Schmidt-Lassen; Daniel Homerick; Wolfram Hänsel; Heike Wulff
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

6.  C-type inactivation of a voltage-gated K+ channel occurs by a cooperative mechanism.

Authors:  G Panyi; Z Sheng; C Deutsch
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

Review 7.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Raymond S Norton
Journal:  Inflamm Allergy Drug Targets       Date:  2011-10

8.  LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability.

Authors:  M J Nadler; M C Hermosura; K Inabe; A L Perraud; Q Zhu; A J Stokes; T Kurosaki; J P Kinet; R Penner; A M Scharenberg; A Fleig
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

9.  Depletion of intracellular calcium stores activates a calcium current in mast cells.

Authors:  M Hoth; R Penner
Journal:  Nature       Date:  1992-01-23       Impact factor: 49.962

10.  The Concise Guide to PHARMACOLOGY 2013/14: ion channels.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

View more
  6 in total

1.  State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.

Authors:  Malika Faouzi; John Starkus; Reinhold Penner
Journal:  Br J Pharmacol       Date:  2015-10-09       Impact factor: 8.739

Review 2.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

Review 3.  Mechanisms Underlying C-type Inactivation in Kv Channels: Lessons From Structures of Human Kv1.3 and Fly Shaker-IR Channels.

Authors:  Seow Theng Ong; Anu Tyagi; K George Chandy; Shashi Bhushan
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.

Authors:  Melissa S Love; Federico C Beasley; Rajiv S Jumani; Timothy M Wright; Arnab K Chatterjee; Christopher D Huston; Peter G Schultz; Case W McNamara
Journal:  PLoS Negl Trop Dis       Date:  2017-02-03

5.  Clofazimine: A Promising Inhibitor of Rabies Virus.

Authors:  Jiajing Wu; Shouchun Cao; Shan Lei; Qiang Liu; Yinghong Li; Yueyang Yu; Hui Xie; Qianqian Li; Xiaoqiang Zhao; Ruifeng Chen; Weijin Huang; Xinyue Xiao; Yongxin Yu; Danqing Song; Yuhua Li; Youchun Wang
Journal:  Front Pharmacol       Date:  2021-03-18       Impact factor: 5.810

Review 6.  Alternative Targets for Modulators of Mitochondrial Potassium Channels.

Authors:  Antoni Wrzosek; Shur Gałecka; Monika Żochowska; Anna Olszewska; Bogusz Kulawiak
Journal:  Molecules       Date:  2022-01-04       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.